Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis
Aflibercept 8 mg demonstrates a comparable efficacy and safety to currently available anti-VEGF treatments for nAMD, with the potential added benefit of requiring fewer injections. These results suggest that aflibercept 8 mg could be a favourable treatment option for nAMD, achieving sustained disease control while alleviating the burden of injections on patients, caregivers, and healthcare providers.
Authors
- Olívia Wu (ORCID: https://orcid.org/0000-0002-0570-6016)
- Paolo Lanzetta (ORCID: https://orcid.org/0000-0003-3746-141X)
- João Carrasco (ORCID: https://orcid.org/0000-0001-7084-2674)
- Marlena Wdowiak
- Xin Zhang (ORCID: https://orcid.org/0000-0001-5008-0879)
- Piotr Wojciechowski
- Jean-François Korobelnik
- Malgorzata Panek
- Izabella Lunk
Institutions
- University of Udine (IT)
- Université de Bordeaux (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bordeaux Population Health (FR)
- Bayer (Switzerland) (CH)
- Istituto Europeo di Microchirurgia Oculare (IT)
- University of Glasgow (GB)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2025-02-24
- DOI
- https://doi.org/10.1007/s40123-025-01098-y
- Citations
- 8
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 13.66
Funders
- Bayer